Both normal and tumor cells with WT p53 showed significant recovery after dose fractionation, while Li-Fraumeni fibroblasts with mutant p53 and defective G1/S checkpoint lost the survival improvement due to dose fractionation (Figure 4a). This evidence concerns the gene TP53 and neoplasm.